Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 9:20 PM
Ignite Modification Date:
2025-12-24 @ 9:20 PM
NCT ID:
NCT06609304
Brief Summary:
The goal of this clinical trial is to learn if Axicabtagene Ciloleucel (axi-cel) works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma (LBCL). It will also learn about the safety of axi-cel treatment. The main questions it aims to answer are:
* Does axi-cel treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment?
* What medical problems do participants have when receiving axi-cel treatment?
In this investigator-initiated, single-arm clinical trial, participants will:
* Receive atezolizumab treatment at 2.0×10\^6 cells/Kg as a one-time therapy.
* Visit the clinic as instructed for checkups and tests.
Study:
NCT06609304
Study Brief:
Protocol Section:
NCT06609304